Nurix Therapeutics (NASDAQ: NRIX) net income
Nurix Therapeutics reported a net loss of $264.5m for fiscal 2025; in fiscal 2024 it reported a net loss of $193.6m. Earnings per share were −$3.05.
Nurix Therapeutics's best year of the last 7 was fiscal 2019. It reported a loss in 7 of those 7 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$264.5m | — | −314.9% | −$3.05 |
| 2024 | −$193.6m | — | −354.9% | −$2.88 |
| 2023 | −$143.9m | — | −187.0% | −$2.65 |
| 2022 | −$180.4m | — | −466.9% | −$3.71 |
| 2021 | −$117.2m | — | −393.9% | −$2.73 |
| 2020 | −$43.2m | — | −242.7% | — |
| 2019 | −$21.7m | — | −69.7% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Nurix Therapeutics net income compared with its sector
By net income for its latest fiscal year, Nurix Therapeutics ranks 438th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Nurix Therapeutics, −314.9%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 436th | Celldex Therapeutics | −$258.8m | −16,748.0% |
| 437th | Brookdale Senior Living | −$262.7m | −8.2% |
| 438th | Nurix Therapeutics | −$264.5m | −314.9% |
| 439th | Ocular Therapeutix | −$265.9m | −511.9% |
| 440th | Lyell Immunopharma | −$274.4m | −762,355.6% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Nurix Therapeutics
- How much did Nurix Therapeutics earn in fiscal 2025?
- Nurix Therapeutics reported a net loss of $264.5m for fiscal 2025. In fiscal 2024 it reported a net loss of $193.6m.
- What are the earnings per share of Nurix Therapeutics?
- They were −$3.05 in fiscal 2025, compared with −$2.88 in fiscal 2024.
- Where does Nurix Therapeutics rank in its sector by net income?
- It ranks 438th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Nurix Therapeutics come from?
- From the annual report (Form 10-K) that Nurix Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Nurix Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on Nurix Therapeutics: the Nurix Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.